1
|
Cassier P, Terret C, Voisin A, Schiffler C, Bidaux AS, Vanacker H, Eberst L, Lepercq M, D'Argenio A, M. Bernardin, Bouhamama A, Gilles-Afchain L, Treilleux I, Tabone-Eglinger S, Spaggiari D, Chabaud S, Grinberg-Bleyer Y, Garin G, Perol D, Vinceneux A. 480P CATRIPCA – A phase I of pembrolizumab (P) combined with Xevinapant (Debio 1143, (X)) in patients (pts) with non MSI-high advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) or colorectal cancer (CRC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
2
|
Sanchez M, Barrere V, Treilleux I, Chopin N, Melodelima D. Development of a noninvasive HIFU treatment for breast adenocarcinomas using a toroidal transducer based on preliminary attenuation measurements. Ultrasonics 2021; 115:106459. [PMID: 33990009 DOI: 10.1016/j.ultras.2021.106459] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/21/2020] [Revised: 01/21/2021] [Accepted: 05/04/2021] [Indexed: 06/12/2023]
Abstract
Breast cancer is the most commonly diagnosed type of cancer among women. For the last fifteen years, treatments that are less invasive than lumpectomy, such as high-intensity focused ultrasound (HIFU) therapy, have been developed, with encouraging results. In this study, a toroidal HIFU transducer was used to create lesions of at least 2 cm in diameter within less than one minute of treatment. The toroidal HIFU transducer created two focal zones that led to large, fast and homogeneous ablations (10.5 cc/min). The experiments were conducted in 30 human samples of normal breast tissues recovered from mastectomies to measure acoustic attenuation (N = 30), and then, HIFU lesions were created (N = 15). Eight HIFU ablations were performed to evaluate the reproducibility of the lesions. HIFU lesions were created in 45 s with a toroidal HIFU transducer working at 2.5 MHz. The longest and shortest axes of the HIFU lesions were 21.7 ± 3.1 mm and 23.5 ± 3.3 mm respectively, corresponding to an average volume of 7.3 ± 1.4 cm3. These HIFU lesions were performed at an average depth of 19.0 ± 1.5 mm, while the integrity of the skin was preserved. The HIFU-treated breast tissues had a higher level of attenuation (0.57 ± 0.11 Np.cm-1.MHz-1) when compared to the untreated tissues (0.21 ± 0.04 Np.cm-1.MHz-1). This study shows the feasibility of a fast and fully noninvasive treatment using a toroidal transducer for breast tumors measuring up to 15 mm in diameter.
Collapse
Affiliation(s)
- M Sanchez
- LabTAU, INSERM, Centre Léon Bérard, Université Lyon 1, Univ Lyon, F-69003 Lyon, France
| | - V Barrere
- LabTAU, INSERM, Centre Léon Bérard, Université Lyon 1, Univ Lyon, F-69003 Lyon, France
| | | | - N Chopin
- Centre Léon Bérard, F-69008 Lyon, France
| | - D Melodelima
- LabTAU, INSERM, Centre Léon Bérard, Université Lyon 1, Univ Lyon, F-69003 Lyon, France.
| |
Collapse
|
3
|
Morfouace M, Ray-Coquard I, Girard N, Stevovic A, Treilleux I, Meeus P, Aust S, Floquet A, Croce S, Seckl M, Gietema J, Caplin M, delaFouchardiere C, Licitra L, Kapiteijn H, Neumann SP, Idbaih A, Blay J. Arcagen: Molecular profiling of rare cancer patients – analysis of the pilot study (87 patients). Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)31155-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
4
|
Derquin F, Floquet A, Hardy-Bessard AC, Edeline J, Lotz JP, Alexandre J, Pautier P, Angeles MA, Delanoy N, Lefeuvre-Plesse C, Cancel M, Treilleux I, Augereau P, Lavoue V, Kalbacher E, Berton Rigaud D, Selle F, Nadeau C, Gantzer J, Joly F, Guillemet C, Pomel C, Favier L, Abdeddaim C, Venat-Bouvet L, Provansal M, Fabbro M, Kaminsky MC, Lortholary A, Lecuru F, Coquard IR, de La Motte Rouge T. Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network. Gynecol Oncol 2020; 158:666-672. [PMID: 32624235 DOI: 10.1016/j.ygyno.2020.06.491] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 06/12/2020] [Indexed: 02/07/2023]
Abstract
BACKGROUND Malignant ovarian germ cell tumors are rare tumors, affecting young women with a generally favorable prognosis. The French reference network for Rare Malignant Gynecological Tumors (TMRG) aims to improve their management. The purpose of this study is to report clinicopathological features and long-term outcomes, to explore prognostic parameters and to help in considering adjuvant strategy for stage I patients. PATIENTS AND METHODS Data from patients with MOGCT registered among 13 of the largest centers of the TMRG network were analyzed. We report clinicopathological features, estimated 5-year event-free survival (5y-EFS) and 5-year overall survival (5y-OS) of MOGCT patients. RESULTS We collected data from 147 patients including 101 (68.7%) FIGO stage I patients. Histology identifies 40 dysgerminomas, 52 immature teratomas, 32 yolk sac tumors, 2 choriocarcinomas and 21 mixed tumors. Surgery was performed in 140 (95.2%) patients and 106 (72.1%) received first line chemotherapy. Twenty-two stage I patients did not receive chemotherapy. Relapse occurred in 24 patients: 13 were exclusively treated with upfront surgery and 11 received surgery and chemotherapy. 5y-EFS was 82% and 5y-OS was 92.4%. Stage I patients who underwent surgery alone had an estimated 5y-EFS of 54.6% and patients receiving adjuvant chemotherapy 94.4% (P < .001). However, no impact on estimated 5y-OS was observed: 96.3% versus 97.8% respectively (P = .62). FIGO stage, complete primary surgery and post-operative alpha fetoprotein level significantly correlated with survival. CONCLUSION Adjuvant chemotherapy does not seem to improve survival in stage I patients. Active surveillance can be proposed for selected patients with a complete surgical staging.
Collapse
Affiliation(s)
- F Derquin
- Medical Oncology Department, Centre Hospitaliser Yves Le Foll, Saint Brieuc, France
| | - A Floquet
- Medical Oncology Department, Institut Bergonié, Bordeaux, France
| | | | - J Edeline
- Medical Oncology Department, Centre Eugène Marquis, Rennes, France
| | - J P Lotz
- Medical Oncology Department, Sorbonne University, APHP, Paris, France
| | - J Alexandre
- Medical Oncology Department, Hôpital Cochin, APHP, Paris, France
| | - P Pautier
- Medical Oncology Department, Institut Gustave Roussy, Villejuif, France
| | - M A Angeles
- Surgical Oncology Department, Institut Claudius Regaud, Toulouse, France
| | - N Delanoy
- Medical Oncology Department, Hôpital Européen Georges Pompidou, APHP, Paris, France
| | | | - M Cancel
- Medical Oncology Department, Centre Hospitalier Universitaire Bretonneau, Tours, France
| | - I Treilleux
- Medical Oncology Department, Centre Léon Bérard, Lyon, France
| | - P Augereau
- Medical Oncology Department, Institut de Cancérologie de l'Ouest, Angers, France
| | - V Lavoue
- Gynecology Department, Centre Hospitalier Universitaire, Rennes, France
| | - E Kalbacher
- Medical Oncology Department, Centre Hospitalier Régional Universitaire, Besançon, France
| | - D Berton Rigaud
- Medical Oncology Department, Institut de Cancérologie de l'Ouest, Nantes, France
| | - F Selle
- Diaconnesses Hospital Group, Paris, France
| | - C Nadeau
- Gynecology Department, CHU de Poitiers, Poitiers, France
| | - J Gantzer
- Medical Oncology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - F Joly
- Medical Oncology Department, Centre François Baclesse, Caen, France
| | - C Guillemet
- Medical Oncology Department, Centre Henri-Becquerel, Rouen, France
| | - C Pomel
- Medical Oncology Department, Centre Jean Perrin, Clermont-Ferrand, France
| | - L Favier
- Medical Oncology Department, Centre Georges François Leclerc, Dijon, France
| | - C Abdeddaim
- Medical Oncology Department, Centre Oscar Lambret, Lille, France
| | - L Venat-Bouvet
- Medical Oncology Department, CHU Dupuytren, Limoges, France
| | - M Provansal
- Medical Oncology Department, Institut Paoli Calmettes, Marseille, France
| | - M Fabbro
- Medical Oncology Department, Institut régional du Cancer Montpellier, Montpellier, France
| | - M C Kaminsky
- Medical Oncology Department, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-Les-Nancy, France
| | - A Lortholary
- Medical Oncology Department, Hôpital Privé du Confluent, Nantes, France
| | - F Lecuru
- Medical Oncology Department, Hôpital Européen Georges Pompidou, APHP, Paris, France
| | - I Ray Coquard
- Medical Oncology Department, Centre Léon Bérard, Lyon, France
| | | |
Collapse
|
5
|
Vinches M, Stevovic A, Ray-Coquard I, Treilleux I, Meeus P, Aust S, Floquet A, Croce S, Chalabreysse L, Girard N, Blay JY, Morfouace M. Arcagen: An EORTC-SPECTA project to perform a molecular characterization of rare cancers: Results of the retrospective feasibility cohort. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz413.086] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
6
|
Fayette J, Digue L, Ségura-Ferlay C, Treilleux I, Wang Q, Lefebvre G, Daste A, Even C, Couchon Thaunat S, Guyennon A, Peyrade F, Cupissol D, You B, Le Tourneau C, Jaouen L, Grinand E, Tabone-Eglinger S, Garin G, Perol D. Buparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: A phase II multicenter trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz252.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Cassier P, Eberst L, Garin G, Courbebaisse Y, Terret C, Robert M, Frenel JS, Depil S, Delord JP, Perol D, Ray-Coquard I, Bidaux AS, Tabone-Eglinger S, Gilles-Afchain L, Treilleux I, Wang Q, Ducarouge B, Mehlen P, Blay JY, Gomez-Roca C. A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Brahmi M, Franceschi T, Treilleux I, Pissaloux D, Ray-Coquard I, Dufresne A, Meeus P, Sunyach MP, Marie K, Meurgey A, Blay JY, Tirode F. The molecular landscape of fusion genes in endometrial stromal sarcomas include three nosological entities with different natural history. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz283.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Desestret V, Pissaloux D, Treilleux I, Small M, Robert M, Rogemond V, Picard G, Psimaras D, Alentorn A, Honnorat J. JS1.1 Specific genetic alterations of breast tumors lead to Yo paraneoplastic cerebellar syndromes. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
Paraneoplastic cerebellar degenerations with anti-Yo antibodies (Yo-PCD) are rare syndromes associated with ovarian or breast cancers and caused by an auto-immune response against neuronal antigens expressed by tumor cells. We previously demonstrated in Yo-PCD ovarian cancers an association between massive infiltration of ovarian tumors by activated immune effector cells and recurrent gains and/or mutations of onconeural Yo genes (CDR2L and CDR2), suggesting that such genetic alterations in ovarian tumor cells may trigger immune tolerance breakdown and initiation of the auto-immune reaction against Purkinje cells.
MATERIAL AND METHODS
We pursued the characterization of Yo-PCD tumors and specifically studied breast cancer by IHC, FISH, CGH array and RNA sequencing analysis of 17 breast Yo-PCD tumors and by comparing their genetic characteristics with 10 sporadic breast tumors and public databases.
RESULTS
We confirmed that specific genetic alterations were also present in breast cancers associated with Yo-PCD. Moreover, this study provides additional evidence for a role of tumor cell specificities in PCD immunopathology by revealing peculiarities in Yo-PCD breast tumors compared to Yo-PCD ovarian cancer. Indeed, not only the CDR2L Yo gene was amplified in 8/9 breast Yo-PCD cancers but also the Erb2/Her2 gene in 15/16 (both genes are on chromosome 17q). In addition to this original Her2 and Yo antigen amplification confirmed by FISH, we observed an overexpression of these proteins by IHC analysis. These Yo-PCD breast cancers are also all negative for hormone receptors (HR). Thus, Yo-PCD breast tumors seem to belong to the molecularly and clinically distinct class of HR-negative and Her2-enriched breast cancers, which represents less than 10 % of breast cancers in the general population. Transcriptomic analysis confirmed that breast Yo-PCD tumors differ by their expression programs from classical breast cancers molecular subtypes.
CONCLUSION
Understanding the tumor genetic features leading to the immune breakdown and anti-tumor immune response as well as nervous tissue attack remains challenging and seems to be specific according to the tumor subtypes. Herein, our results suggest that, despite sharing common genetic alterations (copy number variations and mutations affecting Yo genes), the Yo-PCD immunopathogenesis of breast and ovarian cancers differ by involving different tumor-specific molecular pathways.
Collapse
Affiliation(s)
- V Desestret
- Institut NeuroMyogène, INSERM U1217/UMR CRS 5310, Lyon, France, Lyon, France
- French Reference Center on Paraneoplastic Neurological Syndrome, Hospices civils de Lyon, Lyon, France
| | - D Pissaloux
- Department of Biopathology, Centre Leon Berard, Lyon, France
- Cancer Genomics platform, Department of Translational Research, Centre Leon Berard, Lyon, France
| | - I Treilleux
- Department of Biopathology, Centre Leon Berard, Lyon, France
| | - M Small
- Institut NeuroMyogène, INSERM U1217/UMR CRS 5310, Lyon, France, Lyon, France
- French Reference Center on Paraneoplastic Neurological Syndrome, Hospices civils de Lyon, Lyon, France
| | - M Robert
- Institut NeuroMyogène, INSERM U1217/UMR CRS 5310, Lyon, France, Lyon, France
- University of Lyon, Claude Bernard Lyon1, Lyon, France
| | - V Rogemond
- Institut NeuroMyogène, INSERM U1217/UMR CRS 5310, Lyon, France, Lyon, France
- French Reference Center on Paraneoplastic Neurological Syndrome, Hospices civils de Lyon, Lyon, France
| | - G Picard
- French Reference Center on Paraneoplastic Neurological Syndrome, Hospices civils de Lyon, Lyon, France
| | - D Psimaras
- French Reference Center on Paraneoplastic Neurological Syndrome, Assistante Publique-Hôpitaux de Paris, Paris, France
| | - A Alentorn
- French Reference Center on Paraneoplastic Neurological Syndrome, Assistante Publique-Hôpitaux de Paris, Paris, France
| | - J Honnorat
- Institut NeuroMyogène, INSERM U1217/UMR CRS 5310, Lyon, France, Lyon, France
- French Reference Center on Paraneoplastic Neurological Syndrome, Hospices civils de Lyon, Lyon, France
| |
Collapse
|
10
|
Lefevre S, Lusque A, Joyon N, Arnould L, Penault-Llorca F, MacGrogan G, Treilleux I, Vincent-Salomon A, Haudebourg J, Maran-Gonzalez A, Charafe-Jauffret E, Courtinard C, Franchet C, Verriele V, Brain E, Tas P, Delaloge S, Filleron T, LaCroix-Triki M. Abstract P5-12-05: Phenotypic discordance between primary and metastatic breast cancer (MBC) in a large scale real-life multicentre French cohort. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-12-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Therapeutic options at diagnosis for metastatic breast cancers (MBC) differ largely according to cancer phenotype (namely, hormone receptor (HR) and HER2 status). Reported discordance rates between primary tumor and metastasis vary widely in literature, with a median of 18% for estrogen receptor, 31% for progesterone receptor and 10% for HER2. The present study aimed to compare phenotypic profiles between primary and MBC in the real-life setting.
Patients (pts) and methods:
Epidemio-Strategy and Medical Economics (ESME)MBC data platform (NCT03275311) is a French national, multicenter, observational cohort using clinical trials' methodology for data capture, monitoring and quality controls. At the time of analysis, it comprised data of 16703 consecutive newly diagnosed MBC pts (1/01/08-31/12/14) treated in 18 French comprehensive cancer centres. The primary endpoint was the discordance rate of HR and HER2 status between primary tumor and MBC (biopsy of metastatic site done within 6 months of MBC diagnosis). Only patients with both histological reports available were considered. Potential factors associated with phenotype discordance were assessed in a multivariate logistic regression.
Results: 2933 out of 16703 (17.6%) had a biopsy in the first 6 months of metastatic disease. HR and/or HER2 status was available in 1677 pts. The discordance rate between primary and matched MBC was 14.2% (222/1566) for HR: loss of expression in 72.5%, gain in 27.5%. For HER2, the discordance rate was 7.8% (84/1076): 45.2% of losses and 54.8% of gains of expression. The primary HR+/HER2+ subgroup had the highest rate of changes: 53% (49/92) with either a loss of HR (43%), loss of HER2 (43%) or a loss of both (14%). 18% (33/181) of primary triple-negative breast cancer (TNBC) had a phenotypic change with a majority of HR gain (79%). In multivariate analysis, administration of adjuvant chemotherapy +/- targeted therapy was the sole independent predictor of HR status modification (OR: 1.73, 95%CI 1.27-2.36, p=0.001). The presence of a mixed histology was the only predictor of HER2 discordance (OR =2.57, 95%CI 1.19-5.55, p=0.016).
Patient characteristics Total population (n=16703)Pts with primary and MBC phenotype available (n=1677)Age at metastatic diagnosis Median (range)61 (19-99)60 (24-93)De novo MBC4507 (27.1%)221 (13.2%)Number of metastatic sites Median (range)1 (1-9)2 (1-7)MBC sites Brain1200 (7.2%)138 (8.2%)Visceral7755 (46.4%)928 (55.3%)Non-visceral7748 (46.4%)611 (36.4%)Phenotypic profileN = 2933N=1677TNBC356 (18.5%)272 (19.3%)HR+/HER2-1251 (65.0%)917 (65.2%)HR-/HER2+150 (7.8%)105 (7.5%)HR+/HER2+168 (8.7%)112 (8%)Missing1008271Metastatic site samplingN=2933N=1677Bone692 (24.2%)419 (25.5%)Liver514 (18.0%)355 (21.6%)Skin379 (13.3%)203 (12.4%)Node306 (10.7%)169 (10.3%)Lung258 (9.0%)168 (10.2%)Pleura283 (9.9%)121 (7.4%)CNS/CSF*132 (4.6%)42 (2.6%)Other or multiple296 (10.3%)165 (10.0%)Missing7335* CNS= central nervous system, CSF=cerebro-spinal fluid
Conclusion: Biopsy and phenotype re-evaluation of MBC early in the disease course has a confirmed potential significant therapeutic impact in this large scale real life setting and should be proposed as often as possible.
Citation Format: Lefevre S, Lusque A, Joyon N, Arnould L, Penault-Llorca F, MacGrogan G, Treilleux I, Vincent-Salomon A, Haudebourg J, Maran-Gonzalez A, Charafe-Jauffret E, Courtinard C, Franchet C, Verriele V, Brain E, Tas P, Delaloge S, Filleron T, LaCroix-Triki M. Phenotypic discordance between primary and metastatic breast cancer (MBC) in a large scale real-life multicentre French cohort [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-12-05.
Collapse
Affiliation(s)
- S Lefevre
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - A Lusque
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - N Joyon
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - L Arnould
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - F Penault-Llorca
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - G MacGrogan
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - I Treilleux
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - A Vincent-Salomon
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - J Haudebourg
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - A Maran-Gonzalez
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - E Charafe-Jauffret
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - C Courtinard
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - C Franchet
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - V Verriele
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - E Brain
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - P Tas
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - S Delaloge
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - T Filleron
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| | - M LaCroix-Triki
- Gustave Roussy, Villejuif, France; Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France; APHP - Hôpital Cochin - Service d'Anatomie et Cytologie Pathologiques, Paris, France; Centre GF Leclerc, Dijon, France; Centre Jean-Perrin, Clermont Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Lacassagne, Nice, France; ICM, Montpellier, France; Institut Paoli-Calmettes, Marseille, France; Unicancer R&D, Paris, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Curie, Saint-Cloud, France; Atalante Pathologie, Rennes, France
| |
Collapse
|
11
|
Kassem L, Clézardin P, Treilleux I. RANK expression predicts long term outcome in early luminal breast cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy314.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Moyret-Lalle C, Drouet Y, Treilleux I, Léon S, Viari A, Devouassoux-Shisheboran M, Voirin N, De la Fouchardiere C, Puisieux A, Lasset C. PO-226 Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
13
|
Blay JY, Corset V, Mastier C, Treilleux I, Le Tourneau C, Italiano A, Delord J, Attignon V, Wang Q, Baudet C, Sohier E, Bernardin M, Ben Abdesselem L, D'argenio A, Haddad V, Saintigny P, Perrier L, Chabaud S, Perol D, Trédan O. PROFILER 02 - A multicentric, prospective cohort study aiming to evaluate the added value of a large molecular profiling panel (315 cancer-related gene panel [FoundationOne]) versus a limited molecular profiling panel (74 cancer-related gene panel [CONTROL]) in advanced solid tumours. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx508.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
14
|
Chiannilkulchai N, Pautier P, Genestie C, Bats A, Vacher-Lavenu M, Devouassoux-Shisheboran M, Treilleux I, Floquet A, Croce S, Ferron G, Mery E, Pomel C, Penault-Llorca F, Lefeuvre-Plesse C, Henno S, Leblanc E, Lemaire A, Averous G, Kurtz J, Ray-Coquard I. Networking for ovarian rare tumors: a significant breakthrough improving disease management. Ann Oncol 2017; 28:1274-1279. [DOI: 10.1093/annonc/mdx099] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
|
15
|
Beurrier F, Dutour A, Chen Y, Froc E, Gayet P, Guillermet S, Rizo P, Chopin N, Faure C, Dammaco MA, Klinger S, Ferraioli D, Garin G, Treilleux I. Abstract P3-13-08: Preclinical validation of a new tumor imaging agent targeting αvβ3 to detect breast tumor using NIR-light imaging. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-13-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Surgery is still a essential step for breast cancer treatment. Complete tumor removal during surgery rely on surgeon's ability to differentiate tumor from normal tissue. To date, no intra operative method is available and reliable enough to help the surgeon delineate precisely tumor extension in the adjacent normal tissue. Thus, surgeons rely solely on pre operative imaging techniques to delineate tumor margins. Recent advances made in the field of non-invasive imaging and vectorized nano-size particles have revealed a remarkable potential for improved tumor-margin detection. AngiostampTM is a new fluorescent agent for intra operative imaging. This system provides strong binding on αvβ3 integrin-rich tumor neoangiogenesis. Our general hypothesis is that targeting αvβ3 integrin-rich breast carcinoma neoangiogenesis should provide improved delivery of diagnostic compounds and assist surgeons intra operatively using near-infrared imaging techniques.
We conducted preclinical studies to evaluate the distribution of angiostampTM in vivo in murine breast tumor model and to determine the expression of αvβ3 integrin on human breast specimens.
The capacity of AngiostampTM to target αvβ3 integrin was assessed in 4T1 breast tumor model. After tumor implantation, mices were injected with AngiostampTM or a saline solution. Detection of the tumors was performed at different timepoints (early, progressive and established tumors, N= 24 mices/timepoint) using near infrared (NIR) imaging system (FluobeamTM) to detect fluorescence in tumor tissue.
In parallel, the expression of αvβ3 integrins in normal breast tissue, benign lesions (N=20) and various tumors subtypes (N=120) was assessed by immunohistochemistry.
In mice injected with AngiostampTM, fluorescence was observed only within the tumors with low background. AngiostampTM labeled tumors at all timepoint. No false negative fluorescence was found as confirmed by histopathological analyses.
In humans, the αvβ3 integrin are expressed in normal breast epithelial cells and benign metaplastic or proliferative epithelial lesions. However, due to the density of carcinomatous cells, the level of expression was much higher in breast cancer: 94% of invasive ductal carcinomas and 100% of invasive lobular carcinomas had a membranous staining (moderate to high intensity). Expression in breast cancer was not restricted to tumor subtypes neither hormone receptor expression nor SBR grade.
Based on this preclinical demonstration, AngiostampTM could allow a better intra-operative detection of tumor bed in breast cancer, increasing the efficiency of surgical procedure especially for infraclinic disease and decreasing the rate of second surgery. Preclinical development is ongoing and the first clinical trial is expected in 2017.
Citation Format: Beurrier F, Dutour A, Chen Y, Froc E, Gayet P, Guillermet S, Rizo P, Chopin N, Faure C, Dammaco MA, Klinger S, Ferraioli D, Garin G, Treilleux I. Preclinical validation of a new tumor imaging agent targeting αvβ3 to detect breast tumor using NIR-light imaging [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-13-08.
Collapse
Affiliation(s)
- F Beurrier
- Centre Leon Berard, Lyon, Rhone-Alpes, France; Fluoptics, Grenoble, Isere, France
| | - A Dutour
- Centre Leon Berard, Lyon, Rhone-Alpes, France; Fluoptics, Grenoble, Isere, France
| | - Y Chen
- Centre Leon Berard, Lyon, Rhone-Alpes, France; Fluoptics, Grenoble, Isere, France
| | - E Froc
- Centre Leon Berard, Lyon, Rhone-Alpes, France; Fluoptics, Grenoble, Isere, France
| | - P Gayet
- Centre Leon Berard, Lyon, Rhone-Alpes, France; Fluoptics, Grenoble, Isere, France
| | - S Guillermet
- Centre Leon Berard, Lyon, Rhone-Alpes, France; Fluoptics, Grenoble, Isere, France
| | - P Rizo
- Centre Leon Berard, Lyon, Rhone-Alpes, France; Fluoptics, Grenoble, Isere, France
| | - N Chopin
- Centre Leon Berard, Lyon, Rhone-Alpes, France; Fluoptics, Grenoble, Isere, France
| | - C Faure
- Centre Leon Berard, Lyon, Rhone-Alpes, France; Fluoptics, Grenoble, Isere, France
| | - MA Dammaco
- Centre Leon Berard, Lyon, Rhone-Alpes, France; Fluoptics, Grenoble, Isere, France
| | - S Klinger
- Centre Leon Berard, Lyon, Rhone-Alpes, France; Fluoptics, Grenoble, Isere, France
| | - D Ferraioli
- Centre Leon Berard, Lyon, Rhone-Alpes, France; Fluoptics, Grenoble, Isere, France
| | - G Garin
- Centre Leon Berard, Lyon, Rhone-Alpes, France; Fluoptics, Grenoble, Isere, France
| | - I Treilleux
- Centre Leon Berard, Lyon, Rhone-Alpes, France; Fluoptics, Grenoble, Isere, France
| |
Collapse
|
16
|
Beurrier F, Treilleux I, Chen Y, Froc E, Gayet P, Guillermet S, Rizo P, Chopin N, Faure C, Dammaco D, Klinger S, Ferraioli D, Garin G, Dutour A. Preclinical validation of a new tumor imaging agent targeting aVb3 to detect breast tumor using NIR-light imaging. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw392.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Fayette J, Digue L, Ferlay C, Treilleux I, Garin G, Wang Q, Hebert C, Even C, Cupissol D, Couchon-Thaunat S, Jaouen L, Guyennon A, Le Tourneau C, Lefebvre G, Mailliez A, Matias M, Degardin M, Tartas S, Clapisson G, Perol D. PIK-ORL: A phase II, multicenter trial aiming to evaluate BKM120 in monotherapy in patients (pts) with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) after failure of platin and cetuximab or anti-EGFR-based therapy. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw376.11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Kassem L, Bachelot T, Treilleux I, Zhang C, Le Romancer M. The prognostic impact ofPI3K/AKT/mTORpathway aberrations on luminal breast cancer patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.59] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Moyret-Lalle C, Ruiz E, Bardel C, Treilleux I, Courtois-Cox S, Puisieux A. Specific EMT-inducers signature associates with oncogenic events in breast tumour progression. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61228-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
20
|
Van Long FN, Pion N, Lardy-Cleaud A, Lavergne E, Bourdon J, Chabaud S, Treilleux I, Catez F, Diaz J, Marcel V. Ribosome biogenesis factors: novel clinical markers of breast cancer outcome. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61710-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
21
|
Vincent-Salomon A, Ferrari A, Pivot X, Macgrogan G, Arnould L, Treilleux I, Romieux G, Sertier AS, Thomas E, Tonon L, Boyault S, Kielbassa J, Letexier V, Pauporte I, Birbaum D, Saintigny P, Cox D, Viari A. Abstract P6-07-13: New insights on HER2 amplification from the constitutional and somatic standpoints: Results from the ICGC and SIGNAL/Phare studies. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-07-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER2-positive (HER2+) breast cancers are defined by the amplification and/or overexpression of the human epidermal growth factor receptor (HER2/ERBB2) gene on chromosome region 17q12. Although anti-HER2 targeted therapies have greatly improved treatment of HER2+ breast cancer, the magnitude of benefit varies widely between patients. Deciphering the genomic and genetic heterogeneity of HER2+ breast cancer may provide a basis to better understand their natural history, opening new avenues of treatment.
Methods: As part of the ICGC Breast Cancer Working Group effort, we combined whole genome sequencing and transcriptomic analyses of 64 HER2+ primary invasive carcinomas, and a genome wide association study (GWAS) of over 9.836 breast cancer patients in the prospective SIGNAL/PHARE cohort (NCT00381901 – RECF1098).
Results: Using WGS data we precisely delineate the ERBB2 amplicon as a 106 kb region involving six genes and show that the amplification mechanism was consistent with breakage-fusion-bridge (BFB) cycles. Four RNA expression-based groups were identified, displaying specific genomic alterations in terms of amplification, rearrangements and mutations. On other hand, GWAS analyses failed to identify any constitutional variants associated with HER2 amplification.
Discussion: By combining whole genome sequencing and expression analysis, we provide evidence showing that HER2+ tumours display considerably more molecular heterogeneity than previously reported. These results are reinforced with the lack of association between any genetic variants and HER2 amplification from GWAS analyses. Taken as a whole, these results suggest that HER2+ breast cancers do not represent per se a homogeneous subtype, but are distributed along the whole breast cancer spectrum, from ER-positive luminal to ER-negative basal phenotype. Genome alterations present in HER2+ tumors are in accordance with these phenotypes, and it is likely that the HER2 amplification is a secondary event in the course of tumorigenesis, not favored by any particular constitutional or somatic genetic variants.
Citation Format: Vincent-Salomon A, Ferrari A, Pivot X, Macgrogan G, Arnould L, Treilleux I, Romieux G, Sertier A-S, Thomas E, Tonon L, Boyault S, Kielbassa J, Letexier V, Pauporte I, Birbaum D, Saintigny P, Cox D, Viari A. New insights on HER2 amplification from the constitutional and somatic standpoints: Results from the ICGC and SIGNAL/Phare studies. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-07-13.
Collapse
Affiliation(s)
- A Vincent-Salomon
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - A Ferrari
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - X Pivot
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - G Macgrogan
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - L Arnould
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - I Treilleux
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - G Romieux
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - A-S Sertier
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - E Thomas
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - L Tonon
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - S Boyault
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - J Kielbassa
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - V Letexier
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - I Pauporte
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - D Birbaum
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - P Saintigny
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - D Cox
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| | - A Viari
- Curie Institute, Paris, France; Leon Berard Cancer Center, Lyon, France; Uiniversity Hospital Minjoz, Besançon, France; Cancer Center, Bordeaux, France; GF Leclerc Cancer Center, Dijon, France; Val d'Autel Cancer Center, Montpellier, France; INCa, Paris, France; Inserm - Paoli Calmette Cancer Center, Marseille, France
| |
Collapse
|
22
|
Couder F, Schmitt C, Treilleux I, Tredan O, Faure C, Carrabin N, Beurrier F, Chopin N. [Axillary lymph node metastases with an occult breast: About 16 cases from a cohort of 7770 patients]. ACTA ACUST UNITED AC 2015; 43:588-92. [PMID: 26257298 DOI: 10.1016/j.gyobfe.2015.06.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2015] [Accepted: 06/22/2015] [Indexed: 10/23/2022]
Abstract
OBJECTIVES Isolated axillary lymph node metastases is an unusual clinical presentation of breast carcinoma. We studied its different issues. METHODS This study is a follow-up study of 16patients, treated between 1996 and 2012, presenting with axillary metastases with an occult breast carcinoma, which could not be identified by physical examination nor by a conventional imaging or a breast MRI. Clinical characteristics, histological analysis, treatment, monitoring and five-year survival rate were studied. RESULTS The incidence of this kind of breast cancer was 0.20%. A breast MRI was performed in 75% of the patients. The histology of these tumors showed a rate of hormono-sensibility of 50% and an HER2 overexpression of 44%. Sixty-nine percent of the patients had no breast surgery or radiotherapy; global five-year survival rate for these women was 77.4%±11.5. CONCLUSION The survival rates of this study should lead the practitioner to choose a less aggressive breast therapy. Moreover, the histological characteristics explain the high metastatic potential of these tumors, and relate them to the HER2+ subclass of gene expression patterns of breast carcinomas.
Collapse
Affiliation(s)
- F Couder
- Département de chirurgie oncologique, centre Léon-Bérard, centre de lutte contre le cancer Lyon et Rhône-Alpes, 28, rue Laënnec, 69373 Lyon cedex 08, France
| | - C Schmitt
- Département de chirurgie oncologique, centre Léon-Bérard, centre de lutte contre le cancer Lyon et Rhône-Alpes, 28, rue Laënnec, 69373 Lyon cedex 08, France
| | - I Treilleux
- Département d'anatomo-pathologie, centre de lutte contre le cancer Lyon et Rhône-Alpes, Lyon, France
| | - O Tredan
- Département d'oncologie médicale, centre de lutte contre le cancer Lyon et Rhône-Alpes, Lyon, France
| | - C Faure
- Département de chirurgie oncologique, centre Léon-Bérard, centre de lutte contre le cancer Lyon et Rhône-Alpes, 28, rue Laënnec, 69373 Lyon cedex 08, France
| | - N Carrabin
- Département de chirurgie oncologique, centre Léon-Bérard, centre de lutte contre le cancer Lyon et Rhône-Alpes, 28, rue Laënnec, 69373 Lyon cedex 08, France
| | - F Beurrier
- Département de chirurgie oncologique, centre Léon-Bérard, centre de lutte contre le cancer Lyon et Rhône-Alpes, 28, rue Laënnec, 69373 Lyon cedex 08, France
| | - N Chopin
- Département de chirurgie oncologique, centre Léon-Bérard, centre de lutte contre le cancer Lyon et Rhône-Alpes, 28, rue Laënnec, 69373 Lyon cedex 08, France.
| |
Collapse
|
23
|
Treilleux I, Arnedos M, Cropet C, Wang Q, Ferrero JM, Abadie-Lacourtoisie S, Levy C, Legouffe E, Lortholary A, Pujade-Lauraine E, Bourcier AV, Eymard JC, Spaeth D, Bachelot T. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. Ann Oncol 2015; 26:120-125. [PMID: 25361980 DOI: 10.1093/annonc/mdu497] [Citation(s) in RCA: 64] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Everolimus is an agent frequently associated with specific toxicities. Predictive markers of efficacy are needed to help define which patients could benefit from it. The goal of this exploratory study was to identify potential predictive biomarkers in the mammalian target of rapamycin (mTOR) complex 1 (mTORC1) activation pathway using primary tumor samples collected during the phase II tamoxifen plus everolimus (TAMRAD) trial. PATIENTS AND METHODS Tumor tissues were collected retrospectively from the TAMRAD trial. Immunohistochemistry was carried out using specific antibodies directed toward proteins that result in mTORC1 activation [canonical phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mTOR or alternative pathways]. DNA was extracted from the tumor tissue; mutation screening in the PIK3CA gene (exons 9 and 20) and the KRAS gene (exons 2 and 3) was first carried out using Sanger direct sequencing, and then completed by next-generation sequencing for PIK3CA. An exploratory analysis of everolimus efficacy in terms of a time-to-progression (TTP) increase was carried out in each biomarker subgroup (high versus low expression referring to the median percentage of marked cells). RESULTS A total of 55 primary tumor samples from the TAMRAD trial—25 from the tamoxifen-alone group and 30 from the tamoxifen/everolimus group—were evaluated for biomarkers. The subgroups most likely to have an improvement in TTP with tamoxifen/everolimus therapy, compared with tamoxifen alone, were patients with high p4EBP1, low 4EBP1, low liver kinase B1, low pAkt, and low PI3K. Among the 45 samples screened for mutation status, nine samples (20%; 95% CI 9.6-34.6) had a PIK3CA mutation. KRAS mutation was observed in one patient. CONCLUSIONS A positive correlation between late effectors of mTORC1 activation, a positive correlation between Akt-independent mTORC1 activation, and an inverse correlation between canonical PI3K/Akt/mTOR pathway and everolimus efficacy were observed in this exploratory analysis. However, these correlations need to be validated in larger studies before applying the findings to routine clinical practice.
Collapse
Affiliation(s)
- I Treilleux
- Department of Anatomopathology, Centre Léon Bérard, Lyon
| | - M Arnedos
- Oncology Department, Gustave Roussy, Villejuif
| | - C Cropet
- Biostatistics and Therapeutic Evaluation Unit
| | - Q Wang
- Genomic Platform-Translational Research Laboratory, Centre Léon Bérard, Lyon
| | - J-M Ferrero
- Medical Oncology Department, Centre Antoine Lacassagne, Nice
| | | | - C Levy
- Oncology Department, Centre François Baclesse, Caen
| | - E Legouffe
- Hematology and Oncology Department, Clinique de Valdegour, Nimes
| | - A Lortholary
- Oncology Department, Centre Catherine de Sienne, Nantes
| | - E Pujade-Lauraine
- Oncology Department, Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel-Dieu, Paris
| | - A-V Bourcier
- Hematology and Oncology Department, Centre Hospitalier Départemental Les Oudairies, La Roche-Sur-Yon
| | - J-C Eymard
- Department of Medicine, Institut Jean Godinot, Reims
| | - D Spaeth
- Oncology Department, Centre d'Oncologie de Gentilly, Nancy
| | - T Bachelot
- 2B North Department, Department of Medical Oncology and Cancer Research Center of Lyon, Centre Léon Bérard, Lyon, France.
| |
Collapse
|
24
|
Vendrell J, Nguyen N, Gyorffy B, Léon S, Grisard E, Bachelot T, Treilleux I, Cohen P. 649: ZIRA: A new prognostic biomarker of estrogen receptor-positive (ER+) breast cancers. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50569-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
25
|
Cassier PA, Floquet A, Penel N, Derbel O, Bui N'guyen B, Guastalla JP, Pissaloux D, Treilleux I, Saba CE, Blay JY, Ray-Coquard I. The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors. Ann Oncol 2014; 25:1074-5. [PMID: 24651409 DOI: 10.1093/annonc/mdu045] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- P A Cassier
- Department of Medical Oncology, Centre Léon Bérard, Lyon
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Maillet L, Chopin N, Treilleux I, Bachelot T, Tredan O, Faure C, Caux C, Beurrier F. [Spontaneous regression of breast cancer after biopsy. About two cases]. ACTA ACUST UNITED AC 2014; 42:269-72. [PMID: 24394327 DOI: 10.1016/j.gyobfe.2013.08.017] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2013] [Accepted: 06/27/2013] [Indexed: 10/25/2022]
Abstract
We report two cases of spontaneous regression of breast cancer occurred in our institution. It was about a 34- and an 82-year-old patient. The examination revealed a palpable nodule. In both cases, biopsy revealed a negative immunohistochemical staining for estrogen and progesterone receptors, and HER-2 negative. Histological analysis of the surgical specimen found fibrous tissue rearrangement without carcinoma. In the first case, a sarcoidosis was diagnosed at the same time, the mediastinal nodes mimicked a metastatic cancer. These cases illustrate a rare phenomenon. The main hypothesis is a carcinoma- directed immune response triggered by the biopsy.
Collapse
Affiliation(s)
- L Maillet
- Centre Léon-Bérard, département de chirurgie oncologique, université de Lyon 1, 28, rue Laennec, 69008 Lyon, France
| | - N Chopin
- Centre Léon-Bérard, département de chirurgie oncologique, université de Lyon 1, 28, rue Laennec, 69008 Lyon, France
| | - I Treilleux
- Centre Léon-Bérard, département d'anatomopathologie, université de Lyon 1, 28, rue Laennec, 69008 Lyon, France
| | - T Bachelot
- Centre Léon-Bérard, département d'oncologie médicale, université de Lyon 1, 28, rue Laennec, 69008 Lyon, France
| | - O Tredan
- Centre Léon-Bérard, département d'oncologie médicale, université de Lyon 1, 28, rue Laennec, 69008 Lyon, France
| | - C Faure
- Centre Léon-Bérard, département de chirurgie oncologique, université de Lyon 1, 28, rue Laennec, 69008 Lyon, France
| | - C Caux
- Université de Lyon, 69000 Lyon, France; Université Lyon-1, ISPB, Lyon, 69622, 69000 Lyon, France; Inserm U1052, centre de recherche en cancérologie de Lyon, 69000 Lyon, France; CNRS UMR5286, centre de recherche en cancérologie de Lyon, 69000 Lyon, France; Centre Léon Bérard, plateforme d'innovation en immunomonitoring et immunothérapie, 69008 Lyon, France
| | - F Beurrier
- Centre Léon-Bérard, département de chirurgie oncologique, université de Lyon 1, 28, rue Laennec, 69008 Lyon, France.
| |
Collapse
|
27
|
Merlin JL, Lion M, Wong J, Bachelot T, André F, Treilleux I, Loussouarn D, Bonneterre J, Rios M, Diéras V, Jimenez M, Leroux A, Campone M. Abstract P1-08-27: Quantitative analysis of tumor expression of phosphoproteins from PI3-kinase and MAP-kinase signaling pathways as biomarkers of the biological and clinical activity of trastuzumab and everolimus in breast cancer: Unicancer RADHER phase II trial results. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-08-27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: PI3-kinase (PI3K) and MAP kinase (MAPK) are the main signaling pathways implicated in molecular oncogenesis. In breast cancer, inhibition of these signaling pathways has been largely envisaged by means of targeted therapy. Unicancer RADHER study aimed at evaluating the efficacy of adding everolimus (E) to trastuzumab (T) as preoperative therapy for primary HER2+ operable breast cancer patients and to evaluate molecular response biomarkers. We report here the investigation of the expression of phosphoproteins from PI3K and MAPK signaling pathways as predictive biomarkers of clinical and pathological response as well as pharmacodynamic markers of treatment activity.
Methods: 82 eligible patients were randomized to receive T alone (loading dose 4 mg/kg, then 2 mg/kg/week), or T+E (10 mg/day) for a 6-week pre-operative treatment. Clinical response rate (cRR) was determined from OMS criteria with complete and partial responses being considered as “ responders “ and stable and progressive diseases as “ non responders “. Pathological response rate was evaluated according to Sataloff classification, with Ta and Tb being considered as “ responders “ and, Tc and Td as “ non responders “. The expression levels of phosphorylated-AKT (p-AKT), p-GSK3b, p-S6 kinase, p-MEK1, p-ERK1/2, p-P90RSK, p-IGF1R as well as p-P38MAPK were quantitatively assessed using multiplex bead immuno-assay. All patients had baseline needle frozen biopsies taken before initiation of the treatment, at cycle 4 as an option and at surgery. Before being submitted to total protein extraction, all biopsies were validated by a senior pathologist after HE slide examination to ensure a tumor content >50%. 36 pairs associating baseline + surgery tumor specimens and 4 pairs of baseline + cycle 4 biopsies were eligible for protein extraction. Results: No statistically significant relationship was observed between the expression level of any of the phosphoproteins in the initial biopsies and neither the clinical nor the pathological response, overall. After treatment, as compared to the level of expression measured in the initial biopsies, a significant increase of p-GSK3β, p-MEK1, p-ERK1/2, p-P38MAPK was observed in T+E arm and a significant decrease in p-S6 kinase expression in the global patient population. No significant variation was observed in T arm. Additional analysis with immunohistochemistry data is planned and will be presented.
Conclusion: In the present study, measuring phosphoproteins expression showed that combining E with T, altered the regulation of signaling proteins from PI3-Kinase and MAP-kinase pathways. No response predictive biomarker could be identified among the phosphoproteins analyzed tending to show that the clinical and pathological response to T and T+E should be driven by additional mechanisms. As a whole, these results validate the use of multiplex bead immuno-analysis for determination of phosphorylated signaling proteins in clinical needle biopsies from breast cancer specimens and its prospective evaluation as biomarker for the activity of targeted therapies.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-08-27.
Collapse
Affiliation(s)
- J-L Merlin
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - M Lion
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - J Wong
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - T Bachelot
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - F André
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - I Treilleux
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - D Loussouarn
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - J Bonneterre
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - M Rios
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - V Diéras
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - M Jimenez
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - A Leroux
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| | - M Campone
- Institut de Cancérologie de Lorraine, CNRS UMR 7039 CRAN Université de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CHU-Hôpital G&R Laënnec, Nantes, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut Curie, Hospital, Paris, France; UNICANCER, Paris, France; Institut de Cancérologie de l'Ouest, Centre de Recherche du Cancer Nantes-Angers :UMR-INSERM U892/CNRS 6299, Université de Nantes, Nantes, France
| |
Collapse
|
28
|
Bachelot T, Lefebvre C, Campone M, Levy C, Arnedos M, Bonnefoi H, Dieras V, Treilleux I, Goncalves A, Clapisson G, Jimenez M, Andre F. Abstract S6-07: Genomic characterisation of metastatic samples from breast cancer patients using next generation sequencing. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-s6-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Although several studies have reported genomic characterisation of primary breast tumors, little is known about the genomic alterations of the metastatic tissues. Breast cancer patients who were prospectively enrolled in a trial (SAFIR01) underwent a biopsy of metastasis. The primary aim of this biopsy was to drive the treatment according to the results of whole genome CGH arrays and sanger sequencing on two genes (PIK3CA and AKT1). The results of the clinical trial were previously reported (André et al ASCO 2013). The secondary goal of the biopsies was to perform genomic characterisation of metastases in breast cancer patients. Here we report the analyses of such metastatic samples using next generation sequencing (NGS) approaches.
Patients and methods: Two approaches were applied. In order to describe the incidence of targetable genomic alterations, we performed in depth targeted sequencing on 100 genes (200x coverage) using Illumina HiSeq 2000 (DNA vision). This analysis was performed on 240 metastatic samples. The second approach was more exploratory and aimed at discovering new genes involved in the metastatic process and/or resistance to therapies. In order to achieve this goal, we performed whole exome sequencing in 100 pairs of metastatic tissue (100x) and normal DNA (Integragen Inc, Hiseq platform). Finally, phosphor-S6K staining was performed in 300 samples in order to explore the activation status of mTOR pathway in metastatic disease, and to correlate with genomic data.
Results: Targeted sequencing was performed on 240 metastatic samples in order to report the prevalence of targetable genomic alterations in metastatic breast cancer. Results are available for the first 159 samples. In addition to the already reported PIK3CA (26%) and AKT1 mutations (4%), NGS identified mutations of PTEN (4%), ERBB2 (2%), K-Ras (1%), ATM (2%), CDH1 (2%), GATA3 (2%), PTPN11 (1%), PTPRD (1%), ROS1 (1%). Results on the 81 samples, together with whole exome sequencing (n = 100) and phosphoproteins are being analysed and results will be available mid-november 2013.
Conclusion: This is the first large study that aims at defining the genomic landscape of metastatic samples. Results will provide insights into the prevalence of targetable genomic alterations in metastatic tissue, together with candidate genes involved in the metastatic process and resistance to therapies.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr S6-07.
Collapse
Affiliation(s)
- T Bachelot
- Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; Centre de Cancérologie du Grand Ouest, Nantes, France; Centre Francois Baclesse, Caen, France; Centre Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre Paoli Calmette, Marseille, France; UNICANCER, Paris, France
| | - C Lefebvre
- Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; Centre de Cancérologie du Grand Ouest, Nantes, France; Centre Francois Baclesse, Caen, France; Centre Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre Paoli Calmette, Marseille, France; UNICANCER, Paris, France
| | - M Campone
- Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; Centre de Cancérologie du Grand Ouest, Nantes, France; Centre Francois Baclesse, Caen, France; Centre Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre Paoli Calmette, Marseille, France; UNICANCER, Paris, France
| | - C Levy
- Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; Centre de Cancérologie du Grand Ouest, Nantes, France; Centre Francois Baclesse, Caen, France; Centre Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre Paoli Calmette, Marseille, France; UNICANCER, Paris, France
| | - M Arnedos
- Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; Centre de Cancérologie du Grand Ouest, Nantes, France; Centre Francois Baclesse, Caen, France; Centre Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre Paoli Calmette, Marseille, France; UNICANCER, Paris, France
| | - H Bonnefoi
- Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; Centre de Cancérologie du Grand Ouest, Nantes, France; Centre Francois Baclesse, Caen, France; Centre Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre Paoli Calmette, Marseille, France; UNICANCER, Paris, France
| | - V Dieras
- Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; Centre de Cancérologie du Grand Ouest, Nantes, France; Centre Francois Baclesse, Caen, France; Centre Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre Paoli Calmette, Marseille, France; UNICANCER, Paris, France
| | - I Treilleux
- Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; Centre de Cancérologie du Grand Ouest, Nantes, France; Centre Francois Baclesse, Caen, France; Centre Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre Paoli Calmette, Marseille, France; UNICANCER, Paris, France
| | - A Goncalves
- Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; Centre de Cancérologie du Grand Ouest, Nantes, France; Centre Francois Baclesse, Caen, France; Centre Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre Paoli Calmette, Marseille, France; UNICANCER, Paris, France
| | - G Clapisson
- Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; Centre de Cancérologie du Grand Ouest, Nantes, France; Centre Francois Baclesse, Caen, France; Centre Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre Paoli Calmette, Marseille, France; UNICANCER, Paris, France
| | - M Jimenez
- Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; Centre de Cancérologie du Grand Ouest, Nantes, France; Centre Francois Baclesse, Caen, France; Centre Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre Paoli Calmette, Marseille, France; UNICANCER, Paris, France
| | - F Andre
- Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; Centre de Cancérologie du Grand Ouest, Nantes, France; Centre Francois Baclesse, Caen, France; Centre Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre Paoli Calmette, Marseille, France; UNICANCER, Paris, France
| |
Collapse
|
29
|
Dalenc F, Le Guellec S, Arnould L, Coudert B, Vagner S, Bachelot T, Treilleux I, Debled M, MacGrogan G, Jacot W, Bibeau F, Vanlemmens L, André F, Mathieu MC, Augereau P, Verriele V, Penault-Llorca F, Lacroix-Triki M, Filleron T. Abstract P3-14-13: eIF4E/4EBP1 axis and response to neoadjuvant trastuzumab-based treatment in HER2+ breast cancer – Results of a multicentre French retrospective cohort. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-14-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Despite a growing number of studies exploring the underlying mechanisms, resistance to trastuzumab (TTZ) in HER2+ breast cancer (BC) remains elusive and an important issue in clinical practice. Among the proposed mechanisms, involvement of the PI3K/Akt/mTOR pathway is one of the best characterized. In a previous preclinical and clinical study (n = 54) (Bergé Y et al, SABCS 2009 and [1]), we have shown a significant correlation between eIF4E (a downstream effector of the PI3K/Akt/mTOR pathway) expression level as determined by immunohistochemistry (IHC) on initial tumor biopsy and pathological complete response (pCR) in patients with HER2+ BC treated with a neoadjuvant TTZ-containing regimen. The aim of this study was to validate these findings on an independent and larger cohort of HER2+ BC treated in neoadjuvant setting.
Method
In this multicenter (n = 9) study, 274 patients (pts) with HER2+ BC treated were included. All pts received neoadjuvant chemotherapy regimen containing TTZ, consisting mostly of 3-4 cycles of FEC (5FU, Epirubicin, Cyclophosphamid) followed by 3-4 cycles of TTZ–Docetaxel (n = 116). 74 pts received 6 cycles of TTZ–Docetaxel, 18 received 6 cycles of TTZ–Docetaxel-Cyclophosphamid, 12 received 6 cycles of TTZ–Docetaxel-carbolpatine, and the remaining 54 pts received other regimens. Pathological response was assessed according to Sataloff and Chevallier criteria. Unstained slides from the initial tumor biopsy were centrally collected for biomarkers analysis. Expression levels of eIF4E, p-4EBP1 and pS6 were determined by IHC. An immunoreactive score (IRS) combining the percentage of stained tumor cells and staining intensity was assessed by two pathologists.
Results
Median age at diagnosis was 50 years [range 22–84]. Most pts presented with T2 (52.6%), N1 (53.9%) stage, with a median tumor size of 40mm [range 0-150mm] as determined on clinical examination. Tumors were mainly invasive ductal of no special type (93.8%), of histological grade III (50%) and II (45%), ER+ (54.4%). Breast conserving surgery with free margins was achieved in 50.9% of pts. pCR (breast Sataloff TA) was observed in 53% of pts, and in 47.6% when considering both breast and lymph node response. Out of the 274 pts, 257 had sufficient tumor on the initial biopsy for biomarker analysis. Preliminary results showed a median eIF4E IRS of 6 [range 1-12], with 52.1% of cases displaying a low eIF4E expression level (IRS£6). The agreement for inter-observer assessment of eIF4E status was good (k = 0.618, 95% CI [0.523-0.713]). Scoring of p-4EBP1 and pS6 are ongoing and correlations of pCR with eIF4E/4EBP1 axis will be presented.
Conclusion
In this large multicentre retrospective study, the rate of pCR obtained in neoadjuvant setting of HER2+ BC is similar to those described in the literature. Thorough tumor collection allows biomarkers analysis, which has been specifically focused on downstream effectors of the PI3K/Akt/mTOR pathway.
Reference[1] Zindy P, Bergé Y, Allal B et al. Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors. Cancer Res. 2011;71(12):4068-73.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-14-13.
Collapse
Affiliation(s)
- F Dalenc
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - S Le Guellec
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - L Arnould
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - B Coudert
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - S Vagner
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - T Bachelot
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - I Treilleux
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - M Debled
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - G MacGrogan
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - W Jacot
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - F Bibeau
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - L Vanlemmens
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - F André
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - M-C Mathieu
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - P Augereau
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - V Verriele
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - F Penault-Llorca
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - M Lacroix-Triki
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| | - T Filleron
- Institut Claudius Regaud, Toulouse, France; Centre GF Leclerc, Dijon, France; Institut Curie, Orsay, France; Centre Léon Bérard, Lyon, France; Institut Bergonié, Bordeaux, France; Centre Val d'Aurelle-ICM, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Paul Papin, Angers, France; Centre Jean Perrin, Clermont-Ferrand, France
| |
Collapse
|
30
|
Wiel C, Augert A, Vincent DF, Gitenay D, Vindrieux D, Le Calvé B, Arfi V, Lallet-Daher H, Reynaud C, Treilleux I, Bartholin L, Lelievre E, Bernard D. Lysyl oxidase activity regulates oncogenic stress response and tumorigenesis. Cell Death Dis 2013; 4:e855. [PMID: 24113189 PMCID: PMC3824691 DOI: 10.1038/cddis.2013.382] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2013] [Revised: 09/03/2013] [Accepted: 09/03/2013] [Indexed: 12/23/2022]
Abstract
Cellular senescence, a stable proliferation arrest, is induced in response to various stresses. Oncogenic stress-induced senescence (OIS) results in blocked proliferation and constitutes a fail-safe program counteracting tumorigenesis. The events that enable a tumor in a benign senescent state to escape from OIS and become malignant are largely unknown. We show that lysyl oxidase activity contributes to the decision to maintain senescence. Indeed, in human epithelial cell the constitutive expression of the LOX or LOXL2 protein favored OIS escape, whereas inhibition of lysyl oxidase activity was found to stabilize OIS. The relevance of these in vitro observations is supported by in vivo findings: in a transgenic mouse model of aggressive pancreatic ductal adenocarcinoma (PDAC), increasing lysyl oxidase activity accelerates senescence escape, whereas inhibition of lysyl oxidase activity was found to stabilize senescence, delay tumorigenesis, and increase survival. Mechanistically, we show that lysyl oxidase activity favors the escape of senescence by regulating the focal-adhesion kinase. Altogether, our results demonstrate that lysyl oxidase activity participates in primary tumor growth by directly impacting the senescence stability.
Collapse
Affiliation(s)
- C Wiel
- 1] Inserm U1052, Centre de Recherche en Cancérologie de Lyon [2] CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon [3] Centre Léon Bérard [4] Université de Lyon, Lyon, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Campone M, Bachelot T, Paoletti X, Merlin J, Delaloge S, Loussouarn D, Bonneterre J, Jimenez M, Rios M, Treilleux I. Predictive Value of AKT/MTOR Pathway Immunohistochemical (IHC) Biomarkers for Response to Preoperative Trastuzumab (T) vs Trastuzumab + Everolimus (T + E) in Patients (PTS) with Early Breast Cancer (BC): Unicancer Radher Trial Results. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt084.4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Vilquin P, Villedieu M, Grisard E, Larbi SB, Ghayad S, Bachelot T, Corbo L, Treilleux I, Vendrell J, Cohen P. 989 Acquired Resistance to Aromatase Inhibitors is Paired With Hyper-activation of Akt/mTor Pathway in New Cellular Models of Hormone-dependent Breast Cancer. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71607-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
33
|
Labidi-Galv S, Treilleux I, Bajard A, Tredan O, Meeus P, Guastalla J, Menetrier-Caux C, Blay J, Bendriss-Vermare N, Ray-Coquard I. 8038 POSTER Lymphopenia is an Independent Prognostic Factor in Ovarian Cancer and Could Be Associated With Immune Activation. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72126-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Le Romancer M, Treilleux I, Bouchekioua-Bouzaghou K, Sentis S, Corbo L. Methylation, a key step for nongenomic estrogen signaling in breast tumors. Steroids 2010; 75:560-4. [PMID: 20116391 DOI: 10.1016/j.steroids.2010.01.013] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2009] [Revised: 01/19/2010] [Accepted: 01/21/2010] [Indexed: 10/19/2022]
Abstract
Estrogen receptor alpha (ERalpha) is a member of a large conserved superfamily of steroid hormone nuclear receptors which regulates many physiological pathways by acting as a ligand-dependent transcription factor. Evidence is emerging that estrogens also induce rapid signaling to the downstream kinase cascades; however the mechanisms underlying this nongenomic function remain poorly understood. We have recently shown that ERalpha is methylated specifically by the arginine methyltransferase PRMT1 at arginine 260 in the DNA-binding domain of the receptor. This methylation event is required for mediating the extra-nuclear function of the receptor which would thereby interact with Src/FAK and p85 and propagate the signal to downstream transduction cascades that orchestrate cell proliferation and survival. Of particular interest, a possible role of methylated ERalpha in mammary tumorigenesis is also evident by the fact that, as demonstrated by immunohistochemical studies on a cohort of breast cancer patients, ERalpha is methylated in normal epithelial breast cells and is hypermethylated in a subset of breast cancers. Hypermethylation of ERalpha in breast cancer might cause hyperactivation of cellular kinase signaling, notably of Akt, described as a selective survival advantage for primary tumor cells even in the presence of anti-estrogens. A detailed understanding of the molecular mechanisms that control estrogen signaling in breast cancer is a crucial step in identifying new effective therapies.
Collapse
Affiliation(s)
- M Le Romancer
- Equipe labellisée La Ligue, U590 INSERM, Centre Léon Bérard, 28 rue Laennec, Lyon F-69008, France.
| | | | | | | | | |
Collapse
|
35
|
Grelier G, Voirin N, Ay AS, Cox DG, Chabaud S, Treilleux I, Léon-Goddard S, Rimokh R, Mikaelian I, Venoux C, Puisieux A, Lasset C, Moyret-Lalle C. Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer 2009; 101:673-83. [PMID: 19672267 PMCID: PMC2736830 DOI: 10.1038/sj.bjc.6605193] [Citation(s) in RCA: 158] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2009] [Revised: 06/21/2009] [Accepted: 06/30/2009] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND Dicer, a ribonuclease, is the key enzyme required for the biogenesis of microRNAs and small interfering RNAs and is essential for both mammalian development and cell differentiation. Recent evidence indicates that Dicer may also be involved in tumourigenesis. However, no studies have examined the clinical significance of Dicer at both the RNA and the protein levels in breast cancer. METHODS In this study, the biological and prognostic value of Dicer expression was assessed in breast cancer cell lines, breast cancer progression cellular models, and in two well-characterised sets of breast carcinoma samples obtained from patients with long-term follow-up using tissue microarrays and quantitative reverse transcription-PCR. RESULTS We have found that Dicer protein expression is significantly associated with hormone receptor status and cancer subtype in breast tumours (ER P=0.008; PR P=0.019; cancer subtype P=0.023, luminal A P=0.0174). Dicer mRNA expression appeared to have an independent prognostic impact in metastatic disease (hazard ratio=3.36, P=0.0032). In the breast cancer cell lines, lower Dicer expression was found in cells harbouring a mesenchymal phenotype and in metastatic bone derivatives of a breast cancer cell line. These findings suggest that the downregulation of Dicer expression may be related to the metastatic spread of tumours. CONCLUSION Assessment of Dicer expression may facilitate prediction of distant metastases for patients suffering from breast cancer.
Collapse
Affiliation(s)
- G Grelier
- Université de Lyon, Université Lyon 1, ISPB, Lyon, F-69003, France
- Inserm, U590, Lyon, F-69008, France
- Centre Léon Bérard, Lyon, F-69008, France
| | - N Voirin
- Université de Lyon, Université Lyon 1, Faculté Grange Blanche, CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Lyon, F-69373, France
- Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d’Hygiène, Epidémiologie et Prévention, Lyon, F-69437, France
| | - A-S Ay
- Université de Lyon, Université Lyon 1, ISPB, Lyon, F-69003, France
- Inserm, U590, Lyon, F-69008, France
- Centre Léon Bérard, Lyon, F-69008, France
| | - D G Cox
- Inserm, U590, Lyon, F-69008, France
| | - S Chabaud
- Centre Léon Bérard, Département de Santé Publique, Lyon, F-69008, France
| | - I Treilleux
- Centre Léon Bérard, Service d’Anatomopathologie, Lyon, F-69008, France
| | - S Léon-Goddard
- Centre Léon Bérard, Service d’Anatomopathologie, Lyon, F-69008, France
| | - R Rimokh
- Inserm, U590, Lyon, F-69008, France
- Centre Léon Bérard, Lyon, F-69008, France
| | - I Mikaelian
- Université de Lyon, université Lyon 1, Faculté Grange Blanche, CNRS, UMR5201, Laboratoire de Génétique Moléculaire, Signalisation et Cancer, Lyon, F-69008, France
| | - C Venoux
- Université de Lyon, université Lyon 1, Faculté Grange Blanche, CNRS, UMR5201, Laboratoire de Génétique Moléculaire, Signalisation et Cancer, Lyon, F-69008, France
| | - A Puisieux
- Université de Lyon, Université Lyon 1, ISPB, Lyon, F-69003, France
- Inserm, U590, Lyon, F-69008, France
- Centre Léon Bérard, Lyon, F-69008, France
| | - C Lasset
- Université de Lyon, Université Lyon 1, Faculté Grange Blanche, CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Lyon, F-69373, France
- Centre Léon Bérard, Département de Santé Publique, Lyon, F-69008, France
| | - C Moyret-Lalle
- Université de Lyon, Université Lyon 1, ISPB, Lyon, F-69003, France
- Inserm, U590, Lyon, F-69008, France
- Centre Léon Bérard, Lyon, F-69008, France
| |
Collapse
|
36
|
Penault-Llorca F, Lannes B, Vincent-Salomon A, MacGrogan G, Vilain M, Fermeaux V, Treilleux I, Blanc-Fournier C, Leroux A, Antoine M, Ettore F, Charpin C, Jacquemier J, Escourrou G, Lacroix-Triki M, Gosset P, Sagan C, Arnould L, Couturier J. Fluorescence in situ hybridization (FISH) technique by reference centers for HER2 status determination in metastatic breast cancer: quality assurance results of FISH 2002 study. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-2069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #2069
Background: Concordance between IHC and FISH in local and regional centers was evaluated in the FISH 2002 Study. Primary metastatic breast cancer (MBC) tumor samples were tested by IHC for HER2 status according to in-house techniques at 18 regional (n=871) and 81 peripheral (n=670) centers in France between 2002 and 2006. All samples were tested by FISH at regional centers [Penault-Llorca et al. SABCS 2006]. This second part of the study comprises quality assurance evaluation of FISH techniques.
 Methods: 464 cases were selected according to the protocol and were either re-assessed using archived pictures or retested by 3 reference centers (Clermont-Ferrand, Strasbourg, Paris-Curie). 246 samples were re-assessed and 166 were retested.
 Results:Global discordance combining re-assessment and retesting results was 10.7% in the first half of the study and 5.1% in the second part (p=0.041).
 
 Discussion: Concordance was excellent for negative (100%) and IHC 2+ cases (97%). Among low amplification cases (≥6 and <8 copies), 70% were concordant: discordant cases were mainly interpretation pitfalls of polysomic cases, emphasizing the importance of double-stained FISH analyses. These quality assurance results demonstrate that overall concordance and quality of HER2 status determined by FISH has improved significantly over time. This improvement is likely to be related to introduction of rigorous quality control procedures, training, and education, all of which should be continued.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2069.
Collapse
Affiliation(s)
| | - B Lannes
- 14 Hopitaux Universitaires de Strasbourg, Strasbourg, France
| | | | | | - M Vilain
- 4 Centre Oscar Lambret, CLCC de la Région Nord, Lille, France
| | | | | | | | - A Leroux
- 7 Centre Alexis Vautrin, Vandoeuvre Nancy, France
| | - M Antoine
- 8 Hôpital Tenon APHP, Paris, France
| | - F Ettore
- 16 Centre Antoine Lacassagne, Nice, France
| | - C Charpin
- 9 CHU AP-HM Faculté de Médicine, Marseille, France
| | - J Jacquemier
- 10 Institut Paoli Calmettes Cancer Institute, Marseille, France
| | | | | | - P Gosset
- 11 GHICL-FLM Hopital St Vincent, Lille, France
| | - C Sagan
- 12 Hôpital Nord Laënec, Nantes, France
| | - L Arnould
- 13 Centre G-F Leclerc, Dijon, France
| | | |
Collapse
|
37
|
Fitamant J, Guenebeaud C, Treilleux I, Tabone E, Chabot S, Bernet A, Mehlen P, Bachelot T. Netrin-1: a promising therapeutic target in metastatic breast cancer. Expression analysis in localized and metastatic breast tumors and preclinical validation. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-3075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #3075
Netrin-1, an axon navigation cue was proposed to play a crucial role during colorectal tumorigenesis by regulating apoptosis. The netrin-1 receptors DCC and UNC5H belong to the family of dependence receptors that share the ability to induce apoptosis in the absence of their ligand. Cells expressing one of these dependence receptors are thus dependent on ligand availability to survive. Such a trait confers on these receptors a tumor suppressor activity by preventing uncontrolled cell proliferation.
 We have previously shown in breast cancer that gaining autocrine expression of the ligand netrin-1 would represent for cancer cells a selective advantage. Human and murine netrin-1-expressing mammary metastatic cell lines undergo apoptosis when netrin-1 expression is experimentally decreased or when decoy soluble receptor ectodomains are used. Such treatments prevent metastasis formation in a syngenic mouse model of lung colonization by a mammary cancer cell line (Fitamant et al., PNAS 2008, vol 105).
 In order to assess the clinical importance of netrin-1 expression in human breast cancer, we quantified by Q-RT-PCR the mRNA levels of netrin-1 in primary breast cancer biopsies and studied their correlation to pathological and clinical data. We used frozen tumor samples from 120 breast cancer patients treated in our institution between 1993 and 2000. At diagnosis, median age was 50, median tumor size was 40 mm. 11% of the patients had SBR1 tumor, 46% had SBR2 tumor and 43% had SBR3 tumor. Estrogen receptor was positive for 62% of the patients. 17% of the patients were pN0, M0; 71% were pN+, M0 and 12% already had distant metastasis (M+) at time of diagnosis. Although there is no correlation between netrin-1 expression and tumor size, histological SBR grade or hormone receptor status, there is a strong correlation between high netrin-1 expression and the presence of nodal involvement (p=0,007) or distant metastasis at the time of diagnosis (p<0,0001). We hypothesize that high netrin-1 expression allows an early and rapid metastatic dissemination during tumor development. We are currently exploring netrin-1 expression levels at different metastatic sites and are completing survival analysis of our cohort of patients.
 In parallel, preclinical mice models of xenografts either of human breast cancer cell lines or fresh human breast tumors were used to evaluate netrin-1 targeting strategy. The preliminary results show that disrupting netrin-1 activity appears to be more efficient than a conventional Adryamicin-Cyclophosphamide treatment in decreasing tumor sizes and suppressing lung metastasis.
 These results support netrin-1 as a marker of metastatic dissemination and as a promising therapeutic target in breast cancer progression.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3075.
Collapse
Affiliation(s)
- J Fitamant
- 1 Apoptosis, Cancer and Development Laboratory, CNRS UMR5238, University Lyon I, Lyon, France
| | - C Guenebeaud
- 1 Apoptosis, Cancer and Development Laboratory, CNRS UMR5238, University Lyon I, Lyon, France
| | | | - E Tabone
- 2 Centre Leon Berard, Lyon, France
| | - S Chabot
- 2 Centre Leon Berard, Lyon, France
| | - A Bernet
- 1 Apoptosis, Cancer and Development Laboratory, CNRS UMR5238, University Lyon I, Lyon, France
| | - P Mehlen
- 1 Apoptosis, Cancer and Development Laboratory, CNRS UMR5238, University Lyon I, Lyon, France
| | | |
Collapse
|
38
|
Orlandini F, Treilleux I, Meunier A, Guérin N. [Osteosarcoma of the breast following radiation therapy: a case report]. J Radiol 2008; 89:1097-1100. [PMID: 18772789 DOI: 10.1016/s0221-0363(08)73915-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Affiliation(s)
- F Orlandini
- Service de Radiodiagnostic, Centre Léon Bérard, 28, rue Laennec, 69008 Lyon.
| | | | | | | |
Collapse
|
39
|
Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Caux C, Blay J, Ménétrier-Caux C. Regulatory T cells are recruited and activated within primary breast tumors with an adverse clinical outcome. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)71800-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
40
|
Penault-Llorca F, Lannes B, Arnould L, Vincent-Salomon A, MacGrogan G, Vilain M, Fermeaux V, Treilleux I, Blanc-Fournier C, Couturier J, Groupe d'Etudes des Facteurs Pronos S. Results on quality assurance of fluorescence in situ hybridization (FISH) technique by reference centers for HER2 status determination in metastatic breast cancer (MBC): FISH 2002 study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.22028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Chabaud S, Tredan O, Treilleux I, Bourdes V, Gargi T, Pérol D, Bachelot T. Pathologic node involvement as a prognostic factor in HER2-amplified primary breast cancer (BC) patients (pts) treated without trastuzumab. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.11537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Treilleux I, Chapot B, Goddard S, Pisani P, Angèle S, Hall J. The molecular causes of low ATM protein expression in breast carcinoma; promoter methylation and levels of the catalytic subunit of DNA-dependent protein kinase. Histopathology 2007; 51:63-9. [PMID: 17593081 DOI: 10.1111/j.1365-2559.2007.02726.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
AIMS To investigate whether aberrant methylation of the ATM promoter or loss of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) may be the underlying causes of reduced ATM protein levels often seen in breast tumours. METHODS AND RESULTS Methylation-specific polymerase chain reaction was used to determine the ATM promoter status and DNA-PKcs levels were measured by immunohistochemistry. None of the 74 invasive carcinomas (ICs) studied showed ATM promoter hypermethylation, whereas promoter methylation of CDKN2A/p16 (1.8%) and GSTP1 (15.8%) was detected. Of 92 ICs examined, 68 had reduced DNA-PKcs levels, supporting previous findings that alterations in double-strand break repair are associated with breast cancer pathogenesis. Although no association was found between the DNA-PKcs and ATM scores for the series of 92 tissues and 22/24 tissues with normal DNA-PKcs had reduced ATM, 29 tumours showed low expression of both DNA-PKcs and ATM compared with normal tissues. CONCLUSIONS No evidence was found that the reduction in ATM protein levels seen in breast carcinoma is the result of epigenetic silencing. However, cross-regulation between DNA-PKcs and ATM may be a possible cause in a subset of tumours and warrants further investigation.
Collapse
Affiliation(s)
- I Treilleux
- Centre Régional Léon Bérard, International Agency for Research on Cancer Lyon, France
| | | | | | | | | | | |
Collapse
|
43
|
Dumontet CM, Reed JC, Krajewska M, Treilleux I, Mackey JR, Martin M, Vogel C, Rupin M, Brunel E, Hugh J. BCIRG 001 molecular analysis: Identification of prognostic factors in patients (pts) receiving adjuvant therapy for node- positive (N+) breast cancer (BC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.525] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
525 Background: BCIRG 001 (1,491 pts) demonstrated significant superiority of docetaxel/doxorubicin/cyclophosphamide (TAC) over fluorouracil/doxorubicin/cyclophosphamide (FAC) given as adjuvant therapy for N+ operable BC in terms of disease-free survival (DFS) and overall survival (OS) (Martin et al, N Eng J Med, 2005). This ancillary study was aimed to identify tumor-associated factors related to DFS and OS. Methods: Formalin-fixed primary tumors from pts in BCIRG 001 were analysed by immunohistochemistry. Protocol- specified assessment of histological grade (GR), tumor size (TS), estrogen (ER) and progesterone receptors (PR), lymph node status (LN), HER2, MUC1, Mib, p53, Bcl-2, Bax, Bcl-X, Bag-1, tubulin β isotypes II, III and IV, tau protein and detyrosinated a tubulin was performed. Parameters were scored as the percentage of positive cells and analysed as lower or greater than median values. The samples were randomly split into training (2/3) and validation (1/3) sets. Associations between selected parameters and DFS or OS were tested through univariate analyses using the Kaplan Meier method (log-rank test) on the training set. A backward stepwise Cox regression analysis was performed to identify the final model of prognostic factors on the training set. Multivariate analyses were applied to the validation set. Results: 1,350 samples were split into a training (n=906) and a validation (n=444) set. In univariate GR, TS, LN, ER and PR, Mib, tau protein and HER2 were correlated with DFS in both sets. In multivariate ER, PR, TS, LN, Mib (all p<0.01) and tau (p=0.043) were significantly associated with DFS in the training set. In univariate GR, TS, LN, ER and PR, Mib, MUC1, Bcl-2, tubulin III and IV and tau were correlated with OS in both sets, with a trend for p53. In multivariate ER, TS, LN, Mib, p53 (all p<0.01) and PR (p=0.028) were independently correlated with OS in the training set. Conclusions: These data suggest that tau and p53 are independent markers of DFS and OS, respectively, while Mib is correlated with both DFS and OS in pts receiving these forms of adjuvant chemotherapy for N+ BC. Complementary analyses will be presented. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. M. Dumontet
- INSERM UMR 590, Lyon, France; Burnham Institute for Medical Research, La Jolla, CA; HCL, Lyon, France; Cross Cancer Institute, Edmonton, AB, Canada; Hospital Universitario San Carlos, Madrid, Spain; Lynn Reg Cancer Center, Boca Raton, FL; CIRG, Paris, France; Sanofi Aventis, Paris, France; University of Alberta, Edmonton, AB, Canada
| | - J. C. Reed
- INSERM UMR 590, Lyon, France; Burnham Institute for Medical Research, La Jolla, CA; HCL, Lyon, France; Cross Cancer Institute, Edmonton, AB, Canada; Hospital Universitario San Carlos, Madrid, Spain; Lynn Reg Cancer Center, Boca Raton, FL; CIRG, Paris, France; Sanofi Aventis, Paris, France; University of Alberta, Edmonton, AB, Canada
| | - M. Krajewska
- INSERM UMR 590, Lyon, France; Burnham Institute for Medical Research, La Jolla, CA; HCL, Lyon, France; Cross Cancer Institute, Edmonton, AB, Canada; Hospital Universitario San Carlos, Madrid, Spain; Lynn Reg Cancer Center, Boca Raton, FL; CIRG, Paris, France; Sanofi Aventis, Paris, France; University of Alberta, Edmonton, AB, Canada
| | - I. Treilleux
- INSERM UMR 590, Lyon, France; Burnham Institute for Medical Research, La Jolla, CA; HCL, Lyon, France; Cross Cancer Institute, Edmonton, AB, Canada; Hospital Universitario San Carlos, Madrid, Spain; Lynn Reg Cancer Center, Boca Raton, FL; CIRG, Paris, France; Sanofi Aventis, Paris, France; University of Alberta, Edmonton, AB, Canada
| | - J. R. Mackey
- INSERM UMR 590, Lyon, France; Burnham Institute for Medical Research, La Jolla, CA; HCL, Lyon, France; Cross Cancer Institute, Edmonton, AB, Canada; Hospital Universitario San Carlos, Madrid, Spain; Lynn Reg Cancer Center, Boca Raton, FL; CIRG, Paris, France; Sanofi Aventis, Paris, France; University of Alberta, Edmonton, AB, Canada
| | - M. Martin
- INSERM UMR 590, Lyon, France; Burnham Institute for Medical Research, La Jolla, CA; HCL, Lyon, France; Cross Cancer Institute, Edmonton, AB, Canada; Hospital Universitario San Carlos, Madrid, Spain; Lynn Reg Cancer Center, Boca Raton, FL; CIRG, Paris, France; Sanofi Aventis, Paris, France; University of Alberta, Edmonton, AB, Canada
| | - C. Vogel
- INSERM UMR 590, Lyon, France; Burnham Institute for Medical Research, La Jolla, CA; HCL, Lyon, France; Cross Cancer Institute, Edmonton, AB, Canada; Hospital Universitario San Carlos, Madrid, Spain; Lynn Reg Cancer Center, Boca Raton, FL; CIRG, Paris, France; Sanofi Aventis, Paris, France; University of Alberta, Edmonton, AB, Canada
| | - M. Rupin
- INSERM UMR 590, Lyon, France; Burnham Institute for Medical Research, La Jolla, CA; HCL, Lyon, France; Cross Cancer Institute, Edmonton, AB, Canada; Hospital Universitario San Carlos, Madrid, Spain; Lynn Reg Cancer Center, Boca Raton, FL; CIRG, Paris, France; Sanofi Aventis, Paris, France; University of Alberta, Edmonton, AB, Canada
| | - E. Brunel
- INSERM UMR 590, Lyon, France; Burnham Institute for Medical Research, La Jolla, CA; HCL, Lyon, France; Cross Cancer Institute, Edmonton, AB, Canada; Hospital Universitario San Carlos, Madrid, Spain; Lynn Reg Cancer Center, Boca Raton, FL; CIRG, Paris, France; Sanofi Aventis, Paris, France; University of Alberta, Edmonton, AB, Canada
| | - J. Hugh
- INSERM UMR 590, Lyon, France; Burnham Institute for Medical Research, La Jolla, CA; HCL, Lyon, France; Cross Cancer Institute, Edmonton, AB, Canada; Hospital Universitario San Carlos, Madrid, Spain; Lynn Reg Cancer Center, Boca Raton, FL; CIRG, Paris, France; Sanofi Aventis, Paris, France; University of Alberta, Edmonton, AB, Canada
| |
Collapse
|
44
|
Pavic M, Meeus P, Treilleux I, Droz JP. Malignant teratoma 32 years after treatment of germ cell tumor confined to testis. Urology 2006; 67:846.e11-3. [PMID: 16566989 DOI: 10.1016/j.urology.2005.10.039] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2005] [Revised: 09/26/2005] [Accepted: 10/20/2005] [Indexed: 11/20/2022]
Abstract
After the first 2 years of follow-up, the prognosis of testicular cancer confined to the testis is traditionally considered excellent. We report on a man who presented with a psoas mass, corresponding to a very late relapse of his left testicular cancer initially confined to the testis and confirmed by negative retroperitoneal lymph node dissection. Histologic analysis of the mass revealed malignant teratoma. The patient's history was remarkable because of the very long interval to relapse (32 years) associated with this malignant teratoma. This clinical case illustrates the possibility of late relapses throughout life, whatever the initial stage.
Collapse
Affiliation(s)
- M Pavic
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France
| | | | | | | |
Collapse
|
45
|
Bertucci F, Borie N, Bachelot T, Hermitte F, Jacquemier J, Treilleux I, MacGrogan G, Genève J, Birnbaum D, Viens P. Identification and validation of a genomic predictor to distinguish classes of patients with distinct outcomes among poor prognosis breast tumors after anthracycline-based adjuvant therapy. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)80042-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
46
|
Mac Grogan G, Arnould L, Denoux Y, Charpin-Taranger C, Leroux A, Jacquemier J, Treilleux I, Vilain M, Chenard M, Vincent Salomon A. Comparison of IHC and FISH techniques to determine HER2 status of metastatic breast cancer in France: interim analysis of the FISH 2002 study. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)80247-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
47
|
Ray-Coquard I, Guastalla JP, Treilleux I, Biron P, Blay JY, Curé H, Flechon A, Lotz JP, Méeus P, Mignot L, Raudrant D, Tournigand C, Pujade Lauraine E. Tumeurs rares malignes de l’ovaire. ONCOLOGIE 2005. [DOI: 10.1007/s10269-005-0286-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
48
|
Lebecque S, Goddard S, Pin J, Blay J, Treilleux I. Les cellules dendritiques dans le microenvironnement tumoral. Ann Pathol 2004. [DOI: 10.1016/s0242-6498(04)94036-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
49
|
Angèle S, Jones C, Reis Filho JS, Fulford LG, Treilleux I, Lakhani SR, Hall J. Expression of ATM, p53, and the MRE11-Rad50-NBS1 complex in myoepithelial cells from benign and malignant proliferations of the breast. J Clin Pathol 2004; 57:1179-84. [PMID: 15509680 PMCID: PMC1770474 DOI: 10.1136/jcp.2004.017434] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/03/2004] [Indexed: 11/03/2022]
Abstract
AIMS To analyse the expression of proteins involved in DNA double strand break detection and repair in the luminal and myoepithelial compartments of benign breast lesions and malignant breast tumours with myoepithelial differentiation. METHODS Expression of the ataxia telangiectasia (ATM) and p53 proteins was immunohistochemically evaluated in 18 benign and malignant myoepithelial tumours of the breast. Fifteen benign breast lesions with prominent myoepithelial compartment were also evaluated for these proteins, in addition to those in the MRE11-Rad50-NBS1 (MRN) complex, and the expression profiles were compared with those seen in eight independent non-cancer (normal breast) samples and in the surrounding normal tissues of the benign and malignant tumours examined. RESULTS ATM expression was higher in the myoepithelial compartment of three of 15 benign breast lesions and lower in the luminal compartment of eight of these lesions compared with that found in the corresponding normal tissue compartments. Malignant myoepithelial tumours overexpressed ATM in one of 18 cases. p53 was consistently negative in benign lesions and was overexpressed in eight of 18 malignant tumours. In benign breast lesions, expression of the MRN complex was significantly more reduced in myoepithelial cells (up to 73%) than in luminal cells (up to 40%) (p=0.0005). CONCLUSIONS Malignant myoepithelial tumours rarely overexpress ATM but are frequently positive for p53. In benign breast lesions, expression of the MRN complex was more frequently reduced in the myoepithelial than in the luminal epithelial compartment, suggesting different DNA repair capabilities in these two cell types.
Collapse
Affiliation(s)
- S Angèle
- International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon cedex 08, France
| | | | | | | | | | | | | |
Collapse
|
50
|
Borie N, Viens P, Bertucci F, Jacquemier J, Bachelot T, Treilleux I, Deraco S, Debono S, Hermitte F, Koki A. 589 Gene expression profiling defines new molecular classes and predicts response to adjuvant anthracycline-based treatment in breast cancer patients: development of a biochip to predict prognosis and improve clinical management of breast cancer. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)80597-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|